retatrutide mechanism gip glp-1 glucagon triple agonist Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Retatrutide, a GIP, GLP-1 and

PMID: 40427605

The study also reflects that those taking the medications for weight loss only are significantly more interested in products that offer key nutrients such as: Fortified with vitamins and nutrients (75%) High protein or protein fortified (74%) Gut health support (73%) For those no longer taking the medication, 76% report eating the same amount or less food

The study involved 400449 patients aged 1449-65 years with a body mass index (BMI) between 30 and 45 kg/m or between 27 and 29.9 kg/m with an obesity-related condition

Once treatment starts, users typically follow a weekly dosing schedule, often with gradual dose adjustments based on tolerance and response